|
The document discusses a review of teratology studies on FC 95 and FC 143, concluding that an eye lens defect reported in the original FC 95 rat study was a sectioning artifact and that no teratogenic effects were observed at non-maternally toxic doses, with further teratology studies planned for both compounds.
|
1998 |
AR226-0468
|
pmR679N4o8DkOzBoGGNBxpr1D |
3 |
|
This document summarizes a study by Olsen et al. that investigated the association between serum levels of perfluorooctanoic acid (PFOA) and reproductive hormone changes in male production workers at 3M, finding no significant correlation with estradiol or testosterone levels, although a confounded increase in estradiol was noted among those with the highest PFOA levels.
|
1998 |
AR226-0474
|
jBgK4oXOKNLE9md01ZvDJM5zQ |
10 |
|
The document is a final report from 3M Company detailing an epidemiologic investigation into the effects of perfluorooctanoic acid (PFOA) on plasma cholecystokinin levels and hepatic function among PFOA production workers, finding no positive association between serum PFOA levels and clinical hepatic toxicity.
|
1998 |
AR226-0477
|
wr9n37rNpzOnxdZJ9b7NayDnB |
67 |
|
This document reports on a 90-day oral gavage study conducted by DuPont to assess the subchronic toxicity of Telomer B Alcohol in rats, adhering to U.S. EPA Health Effects Test Guidelines.
|
1998 |
AR226-1342
|
jybgvygEO5KzjJXXNgvaVNO6y |
967 |
|
This document details a two-generation reproduction study of ammonium perfluorooctanoate (APFO) in rats, conducted by Argus Research under EPA guidelines, with noted exceptions to Good Laboratory Practice compliance regarding the analytical portion of the study.
|
1998 |
AR226-1781
|
5LM2L99bymM2J6xM9v9kLJNY8 |
1245 |
|
This document appears to be a data collection form for deer reproduction analysis, detailing information such as the identification number, data collector, date of collection, cause of death, and various measurements and characteristics of the fetuses and doe.
|
1998 |
AR226-1241
|
J3zo7JppD70BwQBM6o9YgqzvB |
26 |
|
The document reports on a study titled "Perfluorooctanoic Acid: Toxicokinetics in the Rat," conducted by E.I. du Pont de Nemours and Company under Good Laboratory Practice standards, sponsored by the Association of Plastics Manufacturers of Europe, focusing on the metabolism and pharmacokinetics of PFOA.
|
1998 |
AR226-1499
|
15vrawvX94bKL4myZVq2vEzba |
212 |
|
This letter from the Department of Health and Human Services addresses a Health Hazard Evaluation regarding employee exposure to perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) at the 3M Corporation in Cottage Grove, Minnesota, finding no noted health effects despite concerns over elevated blood fluoride levels among workers.
|
1998 |
AR226-1781
|
ZwvgRxZeGGXzpGMmv8MkddV8 |
6 |
|
The document outlines a protocol for a 26-week toxicity study of Ammonium Perfluorooctanoate (APFO) in cynomolgus monkeys, sponsored by the APME Ad-Hoc APFO Toxicology Working Group, to evaluate its effects on enzyme levels, hormones, and biochemical parameters.
|
1998 |
AR226-0452
|
q321o9VNy3NND6vGbzwDKjbMG |
18 |
|
The document discusses a review of teratology studies on FC 95 and FC 143, concluding that an eye lens defect previously reported in FC 95 was a sectioning artifact and that teratogenic effects have not been demonstrated at non-maternally toxic doses, with additional studies planned for both compounds.
|
1998 |
AR226-0468
|
mBg9Yz8ZYNkjd0JXJ0BNw4YDB |
3 |
|
The document discusses an epidemiologic study by Olsen et al. examining the relationship between serum PFOA levels and reproductive hormone changes in male production workers at 3M, finding no significant associations with estradiol or testosterone, although a confounded increase in estradiol was noted among those with the highest PFOA levels.
|
1998 |
AR226-0474
|
7r6aEMj2RBLMeZVyBQ8DYVEE |
10 |
|
The document is a final report from 3M Company detailing an epidemiologic investigation of plasma cholecystokinin and hepatic function in production workers exposed to perfluorooctanoic acid (PFOA), which found no positive association between serum PFOA levels and clinical hepatic toxicity.
|
1998 |
AR226-0477
|
pmvq54RXxkQKxLjx7yrpJ2kBk |
67 |
|
The technical report from the University of Rochester summarizes the quantitative analysis of fluorocarbon metabolites, revealing that PFOS was the major metabolite found in rat liver samples treated with FOSA and FOSAA, while significant concentrations of FOSA were also detected in control rats.
|
1998 |
AR226-1812
|
DdGeKpw49DJZjJRLjDn88ygka |
133 |
|
The document provides information on the chemical identification and production process of Perfluorooctanesulfonyl fluoride (POSF) by 3M Company, detailing the use of Simons Electro-Chemical Fluorination (ECF) to synthesize organofluorine molecules.
|
1998 |
AR226-0576
|
nVzNqDmxOpkm4g5Re7roj8g2 |
25 |
|
The document provides information on N-Methyl perfluorooctanesulfonamide (MeFOSA), including its chemical identification, production process by 3M Company using Simons Electro-Chemical Fluorination, and notes that significant production occurs that is non-isolated and non-reportable under TSCA.
|
1998 |
AR226-0581
|
n939vGm9gmodB93NOap4dNQV2 |
20 |
|
The document provides information on N-Ethylperfluorooctylsulfonamido ethanol (EtFOSE), a chemical produced by 3M Company using the Simons Electro-Chemical Fluorination process, detailing its synthesis, distribution, and technical contact information.
|
1998 |
AR226-0582
|
6VK1qVNONnDqVR6dpME27kZd |
24 |
|
The document provides information on N-ethyl perfluorooctanesulfonamido ethyl methacrylate (EtFOSEMA), a chemical produced by 3M Company using the Simons Electro-Chemical Fluorination process, detailing its synthesis and characteristics.
|
1998 |
AR226-0585
|
e5e2r9NvLyykVmgB7EK6nqn5e |
20 |
|
The document provides information about N-Methyl perfluorooctanesulfonamidoethyl acrylate (MeFOSEA), a chemical produced by 3M Company using the Simons Electro-Chemical Fluorination process, detailing its synthesis and distribution.
|
1998 |
AR226-0586
|
KQ7J0G7Jo8Qzyj3nQ1krEGro |
25 |
|
The document is a news media release from the Little Hocking Water Association advising customers to voluntarily reduce water use due to low Ohio River levels affecting wellfield capacity, while highlighting concerns about elevated C-8 (PFOA) levels in Well No. 5, which may need to be activated if demand is not sufficiently reduced.
|
1998 |
AR226-1928
|
pOBdQd228QxxrvRnrR9zgG8D |
2 |
|
The document presents air level trends of C-8 (PFOA) from 1980 to 1983 at a FEE area, showing varying concentrations with a peak of 6.80 mpb recorded for the No. 1 Clean Boom in 1983.
|
1998 |
AR226-1998
|
npeVgaQgwXMbz1mw5Gr0KgRNw |
1 |
|
This document details the results of C-8 (PFOA) exposure sampling at DuPont, indicating various measured levels of PFOA in personal and area samples, with a reset of testing frequency to every 30 days due to some results exceeding action levels.
|
1998 |
AR226-2035
|
mYVYN40ODQzM21EO2BVDpRog |
2 |
|
The document reports that industrial hygiene air sampling results for C-8 (perfluorooctanoic acid, PFOA) at various sample locations in a DuPont facility show higher averages in 1998 compared to 1997, indicating an increase in exposure levels.
|
1998 |
AR226-2038
|
ZBLav5vVErXw6bw6k6NrVjnod |
2 |
|
The memorandum from Jack Offenberger reports rising C-8 (perfluorinated compound) sample results over the past year at various sampling points, indicating an increase in exposure levels compared to the previous year.
|
1998 |
AR226-2039
|
3QyLJ5xgxxvN3QDkpdBeZp883 |
3 |
|
3M Chemicals requested a meeting with the EPA to discuss fluorochemicals, specifically addressing their assessment that current data do not indicate significant health risks from PFOS levels in human populations.
|
1998 |
AR226-0621
|
a1GXNxw7QGdnx2KqxZGQjxgja |
2 |
|
This letter from 3M outlines action items agreed upon with the EPA regarding the development of a product stewardship agreement and the provision of health effects information and exposure assessments related to perfluorooctane sulfonic acid (PFOS).
|
1998 |
AR226-0624
|
GKeyVX9VDgZOp01K2D4n2Q39N |
1 |
|
This memorandum discusses the biodegradation investigation of C-8 (PFOA) at the Washington Works aquifer, reporting a first-order rate constant and half-life estimates for PFOA degradation, while also addressing the need for more accurate measurements of its sorption properties and organic carbon content in the aquifer.
|
1998 |
AR226-1796
|
4azkDorx14L2BR6Zw2rrwDyOQ |
2 |
|
The memorandum discusses the analysis of organic carbon concentration in aquifer materials related to C-8 (perfluorooctanoic acid, PFOA) and estimates a half-life of 47.5 years for its apparent loss in the aquifer, raising questions about the steady state of transport and biodegradation.
|
1998 |
AR226-1797
|
jB4Jqpkdj4jnZzaBOGoBDn4Lk |
1 |
|
The document contains meeting notes from the C-8 PACE Team meetings held on January 6 and 7, 1998, discussing the development and commercialization of alternatives to C-8 (perfluorooctanoic acid, PFOA) and fluoroproducts made without it.
|
1998 |
AR226-2084
|
gv6vd6jZ8DnBmNBz07zv1b1e |
34 |
|
This document discusses the estimation of vapor scavenging coefficients for C-8 (which includes PFOA and PFOS) based on rain event characteristics, emphasizing the assumptions of irreversible absorption into rain droplets and the importance of considering a range of droplet sizes for accurate calculations.
|
1998 |
AR226-2233
|
3ebpBBY20DNn4XpmzXGyzn70y |
3 |
|
This document discusses the estimation of vapor scavenging coefficients for C-8 (likely referring to perfluorooctanoic acid, PFOA) based on rain event characteristics, emphasizing the assumptions made regarding its absorption into rain droplets and the calculation methods used for determining the mass transfer coefficient.
|
1998 |
AR226-2240
|
OEm0YeE6BzNMwR3BVdLz93MZw |
3 |
|
The document outlines a meeting agenda regarding the management of C-8 products, specifically focusing on the status of various projects related to perfluorooctanoic acid (PFOA) and the progress of analytical testing and recovery technologies.
|
1998 |
AR226-2365
|
YDzg0oK6Bv70Mg4kDgnQONwdD |
12 |
|
The document provides analytical results for PFOA concentrations from various sampling locations, including Dry Run Landfill and LeIVtart Landfill, with notable findings of 24,000 ug/L in the Lower Pond at LeIVtart Landfill on May 28, 1998.
|
1998 |
AR226-2451
|
MM8vz0p6ZNnYaYqvmGzwoJx89 |
2 |
|
The memorandum discusses the analysis of water samples for potassium content, indicating issues encountered with sample 5-P-15 due to contamination with Teflon, which resulted in significant equipment damage and additional labor costs.
|
1998 |
AR226-2454
|
yk6JO5mJkGG5OyK2jova1rRdE |
1 |
|
The document is an email from Roger J. Zipfel discussing the analytical results for perfluorooctanoic acid (PFOA) in whole blood, including details about the testing method and expressing interest in salvaging waste Teflon material from the Dordrecht facility.
|
1998 |
AR226-2466
|
BRn7YOpaB7OkG4xEVkwDMxOvw |
1 |
|
The document provides results from environmental sampling of perfluorinated compounds, specifically FC-143, at various landfill sites, detailing concentrations found in leachate and pond samples collected by DuPont in June 1998.
|
1998 |
AR226-2467
|
ZJ2jXGEMdwZp6RqkB9vbdX3a7 |
11 |
|
This document contains analytical results for FC-143 from various sampling locations at the Washington Works site, with data recorded across multiple dates.
|
1998 |
AR226-2493
|
xJqQdKdza5kqvMwNGn6zn880 |
3 |
|
The document is a letter from the EPA approving E.I. duPont's RCRA Facility Investigation Work Plan for its Washington, West Virginia facility, confirming that the company satisfactorily responded to a Notice of Deficiency regarding the investigation of perfluorinated compounds.
|
1998 |
AR226-2546
|
RJn3rnDb5y2n9p10Dj00aq3n8 |
1 |
|
The document reports on a dermal sensitization test using the Buehler method conducted by DuPont to evaluate the sensitization potential of a test substance, adhering to U.S. EPA Good Laboratory Practice Standards with noted exceptions regarding the analysis of treatment solutions.
|
1998 |
AR226-2804
|
O1EQpLBO13oB8kngqrxKdoR3e |
25 |
|
The document details a subchronic toxicity study conducted by E.I. du Pont de Nemours and Company, examining the effects of an unspecified test substance on rats over a 90-day period, in compliance with U.S. EPA Good Laboratory Practice Standards.
|
1998 |
AR226-3243
|
xda5KKd11351LDzwq6N2zwMmg |
215 |
|
The document outlines the 1998 Aarhus Protocol on Persistent Organic Pollutants (POPs), which aims to eliminate discharges and emissions of 16 identified substances, including a ban on certain chemicals and restrictions on others, to protect the environment and human health.
|
1998 |
AR226-3617
|
daEzo4dQr1Mk8dZKg68QmKqdR |
4 |
|
The document outlines the establishment and functions of the Task Force on Persistent Organic Pollutants (POPs) under the Convention on Long-range Transboundary Air Pollution, which was created to address reviews and reassessments required by the 1998 Protocol on POPs, with leadership from Canada and the Netherlands.
|
1998 |
AR226-3618
|
QMvxdzRr8wrvbpzL3DQKmgBaR |
1 |
|
The document outlines the process for proposing new persistent organic pollutants (POPs) for inclusion in the 1998 Protocol on Persistent Organic Pollutants, detailing the technical review of dossiers and guidelines for Parties to submit new substance proposals.
|
1998 |
AR226-3619
|
zMgvvRewvXmGyyZz62ze4J67 |
3 |
|
This document is a final report of an acute dermal irritation/corrosion study conducted by WIL Research Laboratories on the substance H-22481 for E. I. du Pont de Nemours and Company, indicating compliance with Good Laboratory Practice standards despite a deviation in the characterization of the test substance.
|
1998 |
AR226-3086
|
g2Q43z2QOgJyVdK45x2ZdjZE3 |
38 |
|
The document is a final report of an acute dermal irritation/corrosion study conducted by WIL Research Laboratories for E. I. du Pont de Nemours and Company on the substance H-22482, which was performed in compliance with Good Laboratory Practice standards, noting a deviation in characterization that did not affect the study's validity.
|
1998 |
AR226-3087
|
6bMBZ9JRR8BLva6D8yK2833j4 |
38 |
|
The document reports on an eye irritation test conducted by E. I. du Pont de Nemours and Company using a test substance (identified as H-23004) on New Zealand White rabbits, indicating that the substance appeared stable during the study.
|
1998 |
AR226-3088
|
wDMJw8jLG22NYK7qZRJ5dR53V |
10 |
|
This document reports on a static acute 48-hour screening test conducted by DuPont to assess the aquatic toxicity of a perfluorinated compound, indicating that the 48-hour EC50 for Daphnia magna was between 50 and 500 mg/L, with 100% immobilization observed at 5000 mg/L.
|
1998 |
AR226-3089
|
OEy1ok2dZoRB8wKBQOG5BbbD1 |
2 |
|
The document reports that DuPont's H-23005 exhibited slight toxicity in a 96-hour static acute test using fathead minnows (Pimephales promelas) at various concentrations, indicating potential environmental impacts of the substance.
|
1998 |
AR226-3090
|
pmxnRK3bdxV1R35xpVGRQkMMw |
2 |
|
The document reports on a toxicity study conducted by DuPont on PFOA at various concentrations, indicating that exposure resulted in total mortality and slight toxicity at the highest tested levels.
|
1998 |
AR226-3091
|
omoZrqxO2ngrb41XYoVpnaVmg |
2 |
|
The document reports that DuPont's H-22762 exhibited slight toxicity in a 48-hour static acute test using Daphnia magna, indicating potential environmental impacts of the substance.
|
1998 |
AR226-3092
|
Lp139VK3km5vE3onwvzqOKayb |
2 |
|
The document is a Bacterial Reverse Mutation Test study conducted by E. I. du Pont de Nemours and Company, which assessed the mutagenic potential of a test substance related to PFOA, confirming compliance with Good Laboratory Practice standards despite minor deviations.
|
1998 |
AR226-3093
|
k6VLqyMzak9gpVnD57y4VboV |
31 |
|
The document is a final report of an in vitro mammalian cell gene mutation test conducted by E. I. du Pont de Nemours and Company, assessing the mutagenic potential of a substance under Good Laboratory Practice standards, with a noted exception regarding the analysis of treatment solutions that did not affect the study's validity.
|
1998 |
AR226-3094
|
zKVYjeG4Ey6zp9mwO84jjNEm |
31 |
|
The document is a study report from Atochem S.A. detailing the acute oral toxicity of a test substance in rats, conducted by the Centre International de Toxicologie, with a completion date of May 14, 1998.
|
1998 |
AR226-3096
|
np8Mk95JnE3L993yM6X5ydxpm |
23 |
|
The document reports on a study conducted by ConTox Ltd. for E. I. Du Pont de Nemours and Company, which found that the test materials H-23004 and H-23045, along with the control H-23046, did not cause adverse skin responses in a 100-person human patch test, indicating they are not skin irritants or sensitizing agents.
|
1998 |
AR226-3095
|
5bzZqvZqz53KXEEj31qK4QMJ5 |
33 |
|
The document reports on a skin irritation test conducted by E. I. du Pont de Nemours and Company on the substance DuPont-1139, indicating that the test substance appeared stable and showed no evidence of instability during the study.
|
1998 |
AR226-3099
|
DDexdQObEGK9BKYOYYY5v5E1d |
12 |
|
The document reports on an acute dermal irritation study conducted by Elf Atochem S.A. using a test substance on rabbits, completed on May 20, 1998, and adheres to Good Laboratory Practice principles.
|
1998 |
AR226-3098
|
pm29ZwMREokkXrDzqx79mzmrX |
20 |
|
The document reports on a skin irritation test conducted by E. I. du Pont de Nemours and Company on a test substance, evaluating its acute skin irritation potential in rabbits, with no evidence of instability observed during the study.
|
1998 |
AR226-3100
|
bqZdyEypvYgkDr6qZn4V88M1 |
10 |
|
This document is a TNO report detailing an acute inhalation toxicity study of an unspecified perfluorinated compound conducted on rats at the request of ELF Atochem S.A., with findings related to the effects of a 4-hour exposure period.
|
1998 |
AR226-3104
|
ZJadnnjN0k55zQj4vjBRkGjLO |
58 |
|
The document reports on an augmented acute inhalation toxicity study of two different batches of a substance, likely related to PFOA or PFOS, conducted by TNO Nutrition and Food Research Institute, where rats were exposed to limit concentrations for a single 4-hour period and subsequently necropsied for analysis.
|
1998 |
AR226-3105
|
gaKxNgEXqe8yRwQ5Y6ypeabXa |
81 |
|
The document reports on a bacterial reverse mutation test conducted by DuPont on perfluorinated compounds, specifically assessing the mutagenic potential of a test substance using Salmonella typhimurium and Escherichia coli, in compliance with U.S. EPA Good Laboratory Practice Standards.
|
1998 |
AR226-3126
|
3e0kMmydN2DJLK23MBwmgY8Va |
24 |
|
This document reports on a bacterial reverse mutation test conducted by DuPont Pharmaceuticals Company to evaluate the mutagenic potential of a substance, following U.S. EPA and OECD guidelines.
|
1998 |
AR226-3151
|
mq6XrVRVKQpJ8dd6d335b5BKd |
25 |
|
This document reports on a bacterial reverse mutation test conducted by DuPont Pharmaceuticals to evaluate the mutagenic potential of a substance, following U.S. EPA and OECD guidelines.
|
1998 |
AR226-3153
|
YjqRVXm5YOpJBM46EBYzxKEEy |
25 |
|
This document reports on a bacterial reverse mutation test conducted by DuPont Pharmaceuticals to evaluate the mutagenic potential of a substance, following U.S. EPA and OECD guidelines.
|
1998 |
AR226-3154
|
b5jxaERaEanDJyrXv1Epd6896 |
25 |
|
The document reports that ammonium perfluorooctanoate (C-8) has been determined by DuPont to be not likely a human carcinogen or developmental toxin, based on a study involving rats that showed some liver changes and a low incidence of tumors, leading to the establishment of an acceptable exposure limit of 0.01 mg/m³.
|
1998 |
AR226-3373
|
ZBkqzdooL4096aB9Dj7MZEEbp |
4 |
|
The document establishes an Emergency Exposure Limit (EEL) of 50 ppb for C4, C6-Perfluorodiiodoalkane for emergency planning, based on studies indicating significant health effects in rats at higher exposure levels.
|
1998 |
AR226-3393
|
rByy3be1dM2yyOBGkV5pxbvdE |
2 |
|
The document details a bacterial reverse mutation test (Study No. AA47TV.502001.BTL) conducted by Bio Reliance for E. I. du Pont de Nemours and Company, which complies with various GLP regulations but notes that the identity, stability, and concentration of the test substances were not determined.
|
1998 |
AR226-3189
|
995ZEYB30v1g1E0n0yaDnjxK6 |
62 |
|
This document details a subchronic toxicity 90-day gavage study in rats conducted by E.I. du Pont de Nemours and Company, evaluating a trade secret test substance, likely related to PFOA or PFOS, under U.S. EPA Good Laboratory Practice Standards.
|
1998 |
AR226-3184
|
przL18bn547x5w6JDj8mLgXa |
295 |
|
The document details a subchronic toxicity study conducted by DuPont on rats, evaluating the effects of a test substance (not specified) at a dosage of 1000 mg/kg/day, which resulted in minimal liver inflammation and mild alterations in the thyroid gland.
|
1998 |
AR226-3187
|
qajyVzzowgV9Oa15MKxp2ayeR |
260 |
|
The document reports on a subchronic toxicity study conducted by DuPont, evaluating the effects of a 90-day gavage of a test substance on rats, including grip strength assessments, as part of reproductive evaluations.
|
1998 |
AR226-3186
|
oMoRNQjmBEkqgywZo2v6E4em3 |
331 |
|
The document details a 28-day immunotoxicity study on ammonium perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, indicating compliance with U.S. EPA Good Laboratory Practice Standards.
|
1998 |
AR226-3779
|
e13GR1JNx9EM2Vb6w4KMR7YDe |
185 |
|
The document details a subchronic toxicity study conducted by DuPont on rats, evaluating the effects of a 90-day gavage exposure to a perfluorinated compound, with a focus on body and organ weights, as part of reproductive evaluations.
|
1998 |
AR226-3188
|
0gB0JXbqp2O05p1w5ZRJZ00Nm |
341 |
|
This document reports on a subchronic toxicity 90-day gavage study in rats evaluating one-generation reproduction effects of a test substance conducted by E.I. du Pont de Nemours and Company, adhering to U.S. EPA guidelines.
|
1998 |
AR226-3197
|
Lpk7385J7vV0DxM8w9XJozmOw |
316 |
|
The document outlines a 28-day immunotoxicity study of Ammonium Perfluorooctanoate conducted by E.I. du Pont de Nemours and Company, detailing the study's context, guidelines, and quality assurance measures.
|
1998 |
AR226-3780
|
xngBZEY78gX6gz9Y5wboZba1 |
285 |
|
The document reports on a 90-day subchronic toxicity study conducted by DuPont on rats, evaluating the effects of a specific dosage of a perfluorinated compound, including body and organ weights, as part of one-generation reproductive assessments.
|
1998 |
AR226-3201
|
Yrpw5aXeZ18OvxDjbBnavrm6O |
220 |
|
The document reports on a 90-day subchronic toxicity study of an unspecified substance conducted by DuPont, detailing microscopic observations of liver lesions in male rats, including necrosis and inflammation at various dosage levels.
|
1998 |
AR226-3198
|
aQ4Yz5KDog6BnqJG9Ng4r7DR |
333 |
|
The document details a 90-day gavage study on rats conducted by DuPont to evaluate the subchronic toxicity and one-generation reproductive effects of a perfluorinated compound, with clinical and ophthalmological observations recorded throughout the study.
|
1998 |
AR226-3199
|
b5j4LNyQmd8xG38K1beZjrKV6 |
367 |
|
The document details a toxicity test on a mixture containing perfluorooctanesulfonate (PFOS) using the marine algal species Skeletonema costatum, indicating that the test sample, FC-201AF, consists of 3% PFOS among other components, and outlines the methodology and conditions for assessing algal growth inhibition.
|
1998 |
AR226-0695
|
RJ5R2BrxDbm716N2bLVvRRwqX |
34 |
|
The document details a toxicity test on a mixture containing perfluorooctanesulfonate (PFOS) conducted on the marine alga Skeletonema costatum, using a method that assesses algal growth inhibition over a 72-hour exposure period.
|
1998 |
AR226-0732
|
G6LKyOeKODq7gyaGBM9D3paon |
34 |
|
The document details a toxicity test of a mixture containing 1% perfluorooctanesulfonate (PFOS) conducted on the marine alga Skeletonema costatum, using a method to assess algal growth inhibition over a 72-hour exposure period.
|
1998 |
AR226-0846
|
DdGxRKn63zQNmYGZ9R2p2JBv5 |
35 |
|
The document details a toxicity test on a mixture containing perfluorooctanesulfonate (PFOS) using the marine algal species Skeletonema costatum, conducted to assess the acute effects on algal growth under specific conditions.
|
1998 |
AR226-0859
|
6wvn2nZpmvGwvJO32ggGE2DzE |
34 |
|
Empty document.
|
1998 |
AR226-0612
|
zzxRz6dN8vebrkQwK1Z75JmRa |
1 |
|
The document reports that a review of liver tissue sections from monkeys in a 4-week oral rangefinder study of PFOS conducted by Covance found no evidence of compound-related effects or liver necrosis, even in high dose animals.
|
1998 |
AR226-0612
|
82r725vOrZYm2ZjyqppbgjOGe |
1 |
|
The document outlines a corporate toxicology study conducted by 3M on FC-129, focusing on its absorption, distribution, metabolism, and excretion (ADME) in rats, with the objective of identifying persistent metabolites.
|
1998 |
AR226-0612
|
rpmK51L22k2QmZmaLrKNr54V0 |
1 |
|
The document reports on a developmental toxicity study of N-EtFOSE (N-Ethyl-Perfluoroocyanesulfonamido Ethanol) in pregnant rats, finding no teratogenic effects at any dose level, with maternal and fetal toxicity observed at doses of 10 and 20 mg/kg, and establishing a maternal and fetal toxic NOEL of 5 mg/kg.
|
1998 |
AR226-0612
|
6Bj0QyNeN4pqd93gGE98M9RJg |
1 |
|
Empty document.
|
1998 |
AR226-0979
|
ykjwGZJavzZr44eK2ZaDYK3D |
1 |
|
The document is a final report from Corning Hazleton Inc. detailing a primary dermal irritation/corrosion study of the substance T-6684, sponsored by 3M, conducted in accordance with OECD guidelines.
|
1997 |
AR226-0321
|
4vaa39GQmXZQxjOvMQEvV68va |
27 |
|
The document is a final report on a Primary Eye Irritation/Corrosion Study of T-6684, sponsored by 3M and conducted by Corning Hazleton Inc. in accordance with OECD guidelines, with a completion date of January 28, 1997.
|
1997 |
AR226-0322
|
LJr2o3erDo5J7en3Zxr28QXYz |
31 |
|
The document is a final report on a single-dose intravenous pharmacokinetic study of T-6684 in rabbits, sponsored by 3M, conducted by Corning Hazleton, with a completion date of December 31, 1997.
|
1997 |
AR226-0979
|
J3N7JRea9MVrGJr82y60zQYev |
36 |
|
The document is a final report from Covance Laboratories detailing a 5-daily dose dermal absorption/toxicity study of the substance T-6684, sponsored by 3M, conducted on rabbits, with a completion date of December 31, 1997.
|
1997 |
AR226-0979
|
3QZD5bQ4LyVLozmDmNO1xYLK0 |
53 |
|
The document details a study on the atmospheric stability of perfluorooctanesulfonyl fluoride (POSF), conducted by 3M, which involved indirect gas phase photolysis to analyze its behavior under UV radiation.
|
1997 |
AR226-1030
|
QgEyYJO4m8B4XzqX9EpaqND3o |
2 |
|
The document details a study on the atmospheric stability of perfluorooctanesulfonyl fluoride (POSF), conducted by 3M, using indirect gas phase photolysis to analyze its reaction with ozone and other reagents under UV radiation.
|
1997 |
AR226-1030
|
7RjYDqzMJO7Zz1JRqO6pN0pjE |
2 |
|
The document details a 19F-NMR spectral analysis conducted by 3M Specialty Adhesives & Chemicals to determine the identities and relative concentrations of fluorochemical isomers and impurities in the sample FC-95, lot # 217, revealing specific compositional results.
|
1997 |
AR226-0564
|
N2ygYDMejXNrv21rJZor8Kzn8 |
2 |
|
The document provides information on the chemical identification and synthesis process of Perfluorooctane sulfonamido ethyl acetate (PFOSSA), including details about its production by 3M Company using the Simons Electro-Chemical Fluorination process.
|
1997 |
AR226-0578
|
DM2wJRrV01KBKxv53mYX7Ra4Q |
13 |
|
The document provides information on the voluntary use and exposure profile of Perfluorodecane sulfonate (PDSF), including its chemical identification, manufacturing process by 3M Company, and details about its production and distribution.
|
1997 |
AR226-0579
|
nmnD4MmbmagqDQZ2GXryv4R0w |
12 |
|
The document provides information on N-ethyl perfluorooctanesulfonamide (EtFOSA), including its production by 3M Company using the Simons Electro-Chemical Fluorination process, with an estimated off-site distribution of 59% of the less than 100,000 lbs manufactured.
|
1997 |
AR226-0580
|
2JRp4pxMvxMqpV6pG07vB7b0L |
23 |
|
The document provides information on N-methyl perfluorooctanesulfonamido ethanol (MeFOSE), a chemical produced by 3M Company using the Simons Electro-Chemical Fluorination process, detailing its synthesis, production volume, and distribution estimates.
|
1997 |
AR226-0583
|
0gwNV9XkMBQ4EV3ydQxX18Krd |
23 |
|
The document details an acute toxicity test of a mixture containing 3% perfluorooctanesulfonate (PFOS) on the marine copepod Acartia tonsa, using ISO/DIS 14669-1997 methodology to assess lethal effects over a 48-hour exposure period.
|
1997 |
AR226-0696
|
B8BxYYK8Bbk56dR2rvOEG89mk |
34 |
|
The document details an acute toxicity test of a mixture containing perfluorooctanesulfonate (PFOS) on the marine copepod Acartia tonsa, indicating that the test sample, FC-203, comprises 1.34% PFOS along with various other components, and outlines the methodology used for assessing toxicity.
|
1997 |
AR226-0731
|
k6G38RJ25opb5Gjd0bGbm584V |
34 |
|
This document reports on a biodegradation test of a mixture containing perfluorooctanesulfonate (PFOS) conducted by 3M Company, indicating that the chemical oxygen demand (COD) and biochemical oxygen demand (CBOD) values were measured, but the study lacks analytical confirmation of the sample's purity and the fluorochemical proportion.
|
1997 |
AR226-0768
|
8V1z3jvYjxLRZq7dejyLYL3ey |
6 |
|
The document details a Microbics Microtox toxicity test conducted on a mixture containing 0.85% PFOS, indicating that the test sample, FC-203FC, was evaluated for its toxic effects on the organism Photobacterium phosphoreum, although the data may not accurately reflect the toxicity of the fluorochemical component due to incompletely characterized impurities.
|
1997 |
AR226-0769
|
BRKX7G3o2GnORjbQeQK029Kd4 |
9 |
|
The document details an activated sludge respiration inhibition test conducted on a mixture containing perfluorooctanesulfonate (PFOS) produced by 3M, indicating that the test was performed according to OECD Guideline 209 to assess the toxicity of the fluorochemical component.
|
1997 |
AR226-0770
|
wgnB2RNpQYDeav3rqb38dG7NQ |
10 |